The results (Figure 2C) demonstrated that SLC39A1 was highly expressed in LIHC patients, SLC39A4 was highly expressed in CESC and PAAD patients, and SLC39A8 was highly expressed in KIRP patients. This evidence concerns the gene SLC39A4 and pancreatic adenocarcinoma.